Lunsumio (Mosunetuzumab-axgb)

Lunsumio (mosunetuzumab-axgb) is a bispecific CD20-directed CD3 T-cell engager used to treat adult patients with relapsed or refractory follicular lymphoma after a couple of or multiple lines of systemic therapy.

Note: The conditional approval is based on the response rate. Studies are going on to establish how well the medicine works.

Recommended Dosage:  Premedicate prior to each dose in Cycle 1 and 2 to reduce the risk of cytokine release syndrome (CRS) and infusion-related reactions. Administer only as an intravenous (IV) infusion. Each cycle is 21 days. The recommended dosage regimen of Lunsumio is as follows:

• Cycle 1 (Day 1): 1 mg administered intravenously over at least 4 hours.
  
• Cycle 1 (Day 8): 2 mg administered intravenously over at least 4 hours.
  
• Cycle 1 (Day 15): 60 mg administered intravenously over at least 4 hours.
  
• Cycle 2 (Day 1): 60 mg administered intravenously over 2 hours if infusion in Cycle 1 was well-tolerated
  
• Cycle 3 and subsequent cycles (Day 1): 30 mg administered intravenously over 2 hours if infusion in Cycle 1 was well-tolerated

• Lunsumio treatment can cause cytokine release syndrome (CRS), including serious or hazardous reactions. Those who experience CRS (or other side effects that impair consciousness) should be assessed and instructed not to drive and to refrain from operating machinery until resolution.
• Therapy with mosunetuzumab can cause serious neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Assess patients for neurologic toxicity during treatment. At the initial sign of neurologic toxicity, including ICANS, promptly assess the patient, and consider neurology assessment as required.
• Lunsumio 1 mg/30 mg can be responsible for causing severe or fatal infections. Monitor patients for signs and symptoms of infection before and throughout the treatment and treat effectively. It should not be used in the presence of current or active infection.
• Lunsumio injection can be responsible for causing severe or critical cytopenias, including anemia, neutropenia, and thrombocytopenia. Monitor complete blood counts (CBC) throughout therapy. On behalf of the severity of cytopenias, temporarily interrupt, or permanently stop treatment. 
• Lunsumio can cause critical tumor flare. All those with bulky tumors located in near proximity to airways or a vital organ need to be monitored precisely during the first therapy. Monitor patients for compression or obstruction because of mass effect secondary to tumor flare. 
• As per the mechanism of action, this drug may cause fetal harm if administered to a pregnant woman. Females of reproductive age/potential should use suitable contraception ways during treatment and for 3 months following the last dose.

What documents are required to import LUNSUMIO to India?

LUNSUMIO (mosunetuzumab-axgb) injection can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patients ID proof (issued by the government of India)

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
  
• Import permit if applicable

LUNSUMIO (mosunetuzumab-axgb injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Lunsumio in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  

IPN (Indian Pharma Network) can facilitate the supply of LUNSUMIO (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Lunsumio 1 mg/30 mg price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the LUNSUMIO (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Lunsumio®?

Mosunetuzumab-axgb is a Generic Name for the trade name drug Lunsumio®.

What is the Manufacturer’s Name of Lunsumio®?

Lunsumio® is manufactured by Genentech, Inc.

Is Lunsumio® approved by the FDA?

Yes, Lunsumio® is approved by the FDA. Date of approval: December 22, 2022.

Where can I get Lunsumio® at the best price in India?

To get the best Lunsumio price in India, kindly connect with the Indian Pharma Network (a WHO GDP & ISO 9001:2008 certified company). For Lunsumio®, a medical prescription is required from a treating physician.

What is the dosage and form of Lunsumio® supplied?

Lunsumio® is supplied as Injections: 1 mg/mL and 30 mg/30 mL (1 mg/mL) solution in a single-dose vial for intravenous administration. 

What are the most common side effects of Lunsumio®? 

The most common side effects of Lunsumio® are rash, cytokine release syndrome, pyrexia, fatigue, and headache. 

How much does Lunsumio® cost in India?

The cost of Lunsumio in India can vary. In order to procure this follicular lymphoma medication legally, you can Call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Lunsumio®?

Store refrigerated at 2-8°C (36-46°F) in the original carton to protect from light. It is not advisable to freeze or shake it. 

Is it safe to buy Lunsumio® online in India?

Yes, one can buy Lunsumio online in India at the lowest price from the Indian Pharma Network (IPN) if the medicine Lunsumio® is not (yet) registered or available in their country. We can help facilitate the supply of Lunsumio® through legal channels.